CSL Ltd (CSL) - Total Assets

Latest as of June 2025: AU$39.54 Billion AUD ≈ $27.98 Billion USD

Based on the latest financial reports, CSL Ltd (CSL) holds total assets worth AU$39.54 Billion AUD (≈ $27.98 Billion USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.

CSL Ltd - Total Assets Trend (1993–2025)

This chart illustrates how CSL Ltd's total assets have evolved over time, based on quarterly financial data. Also see CSL Ltd (CSL) total market value for the company's overall valuation and market capitalisation.

CSL Ltd - Asset Composition Analysis

Current Asset Composition (June 2025)

CSL Ltd's total assets of AU$39.54 Billion consist of 30.1% current assets and 69.9% non-current assets. Review CSL Ltd (CSL) total liabilities to assess the company's total debt and financial obligations.

Asset Category Amount (AUD) % of Total Assets
Cash & Equivalents AU$0.00 5.5%
Accounts Receivable AU$2.88 Billion 7.3%
Inventory AU$6.47 Billion 16.4%
Property, Plant & Equipment AU$9.80 Billion 24.9%
Intangible Assets AU$8.12 Billion 20.6%
Goodwill AU$8.06 Billion 20.5%

Asset Composition Trend (1993–2025)

This chart illustrates how CSL Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See CSL stock price for real-time trading data and today's change.

Key Asset Composition Facts

  • Current vs. Non-Current Assets: CSL Ltd's current assets represent 30.1% of total assets in 2025, a decrease from 46.3% in 1993.
  • Cash Position: Cash and equivalents constituted 5.5% of total assets in 2025, up from 2.8% in 1993.
  • Tangible vs. Intangible: Intangible assets (including goodwill) make up 40.0% of total assets, an increase from 1.0% in 1993.
  • Asset Diversification: The largest asset category is property, plant & equipment at 24.9% of total assets.

CSL Ltd Competitors by Total Assets

Key competitors of CSL Ltd based on total assets are shown below.

Company Country Total Assets
argenx NV ADR
NASDAQ:ARGX
USA $10.03 Billion
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
USA $1.26 Billion
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
China CN¥37.98 Billion
Halozyme Therapeutics Inc
NASDAQ:HALO
USA $2.22 Billion
Tubize-Fin
BR:TUB
Belgium €1.99 Billion
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
USA $792.26 Million
Nanobiotix
NASDAQ:NBTX
USA $67.76 Million
Innovita Biological Technology Co. Ltd. A
SHG:688253
China CN¥2.23 Billion

CSL Ltd - Liquidity and Working Capital Analysis

Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.

Key Liquidity Metrics

Metric Current 1 Year Ago 5 Years Ago
Current Ratio 2.46 2.18 3.01
Quick Ratio 1.12 0.97 1.37
Cash Ratio 0.00 0.00 0.00
Working Capital AU$7.06 Billion AU$5.82 Billion AU$4.30 Billion

CSL Ltd - Advanced Valuation Insights

This section examines the relationship between CSL Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.

Key Valuation Metrics

Current Price-to-Book Ratio 3.17
Latest Market Cap to Assets Ratio 1.52
Asset Growth Rate (YoY) 3.6%
Total Assets AU$39.40 Billion
Market Capitalization $59.82 Billion USD

Valuation Analysis

Above Book Valuation: The market values CSL Ltd's assets above their book value (1.52x), reflecting positive investor sentiment about the company's future prospects.

Positive Asset Growth: CSL Ltd's assets grew by 3.6% over the past year, showing continued investment in the company's operational capacity.

Annual Total Assets for CSL Ltd (1993–2025)

The table below shows the annual total assets of CSL Ltd from 1993 to 2025.

Year Total Assets Change
2025-06-30 AU$39.40 Billion
≈ $27.88 Billion
+3.63%
2024-06-30 AU$38.02 Billion
≈ $26.90 Billion
-30.15%
2023-06-30 AU$54.43 Billion
≈ $38.52 Billion
+32.05%
2022-06-30 AU$41.22 Billion
≈ $29.17 Billion
+127.02%
2021-06-30 AU$18.16 Billion
≈ $12.85 Billion
+17.42%
2020-06-30 AU$15.46 Billion
≈ $10.94 Billion
+26.07%
2019-06-30 AU$12.27 Billion
≈ $8.68 Billion
+14.28%
2018-06-30 AU$10.73 Billion
≈ $7.60 Billion
+17.66%
2017-06-30 AU$9.12 Billion
≈ $6.45 Billion
+20.39%
2016-06-30 AU$7.58 Billion
≈ $5.36 Billion
+55.68%
2015-06-30 AU$4.87 Billion
≈ $3.44 Billion
-22.46%
2014-06-30 AU$6.28 Billion
≈ $4.44 Billion
+5.06%
2013-06-30 AU$5.98 Billion
≈ $4.23 Billion
-0.83%
2012-06-30 AU$6.03 Billion
≈ $4.26 Billion
+4.01%
2011-06-30 AU$5.79 Billion
≈ $4.10 Billion
+41.62%
2010-06-30 AU$4.09 Billion
≈ $2.89 Billion
-13.94%
2009-06-30 AU$4.75 Billion
≈ $3.36 Billion
+5.81%
2008-06-30 AU$4.49 Billion
≈ $3.18 Billion
+48.79%
2007-06-30 AU$3.02 Billion
≈ $2.14 Billion
+31.67%
2006-06-30 AU$2.29 Billion
≈ $1.62 Billion
+2.48%
2005-06-30 AU$2.24 Billion
≈ $1.58 Billion
-17.43%
2004-06-30 AU$2.71 Billion
≈ $1.92 Billion
+166.85%
2003-06-30 AU$1.02 Billion
≈ $718.44 Million
-22.00%
2002-06-30 AU$1.30 Billion
≈ $921.05 Million
+180.08%
2001-06-30 AU$464.77 Million
≈ $328.86 Million
+37.04%
2000-06-30 AU$339.16 Million
≈ $239.98 Million
+36.06%
1999-06-30 AU$249.27 Million
≈ $176.37 Million
+24.21%
1998-06-30 AU$200.68 Million
≈ $142.00 Million
-47.90%
1997-06-30 AU$385.18 Million
≈ $272.54 Million
+30.58%
1996-06-30 AU$294.99 Million
≈ $208.72 Million
+23.38%
1995-06-30 AU$239.09 Million
≈ $169.17 Million
-23.53%
1994-06-30 AU$312.67 Million
≈ $221.24 Million
+204.58%
1993-06-30 AU$102.66 Million
≈ $72.64 Million
--

About CSL Ltd

AU:CSL Australia Biotechnology
Market Cap
$59.82 Billion
AU$84.54 Billion AUD
Market Cap Rank
#457 Global
#9 in Australia
Share Price
AU$174.26
Change (1 day)
+1.57%
52-Week Range
AU$92.24 - AU$220.70
All Time High
AU$321.70
About

CSL Limited engages in the research, development, manufacture, market, and distribution of biopharmaceutical products and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment manufactures, markets, and distributes plasma produ… Read more